Once-weekly Byetta better than Lantus in Phase III trial
This article was originally published in Scrip
Executive Summary
Lilly/Amylin's once-weekly version of the twice-daily injectable diabetes drug Byetta (exenatide) has been shown in a head-to-head Phase III trial, DURATION-3, to provide slightly improved glucose control, weight loss as opposed to weight gain, and a lower incidence of hypoglycaemia compared with Sanofi-Aventis's once-daily insulin analogue Lantus (insulin glargine), which could bode will for the drug's approval.